Market News

Stay updated with the latest market trends, earnings, and economic indicators.

Showing news for:AKUMSFinancial Services
Clear all filters
Sun Pharma secures relief in 'Pantocid' trademark dispute
positive
ET Markets - Industry 8d ago

Sun Pharma secures relief in 'Pantocid' trademark dispute

Delhi High Court has halted Ahmedabad-based Finecure Pharmaceuticals from producing and selling drugs with names similar to Sun Pharma's 'Pantocid'. The court permitted Finecure to sell existing stock of 'Pantopacid' within four months, provided an affidavit detailing the inventory is filed. This decision overturns a previous ruling that had refused to grant an injunction against Finecure, highlighting significant sales disparities between the two companies.

AAREYDRUGSABGSECAKUMSSPARCFinancial ServicesHealthcare
Market Trading Guide: Akums Drugs among 4 stock recommendations for Thursday
positive
ET Markets - Stocks 31d ago

Market Trading Guide: Akums Drugs among 4 stock recommendations for Thursday

Domestic equities ended lower amid global uncertainty and caution ahead of key US inflation data. Despite market weakness, analysts remain bullish on Akums Drugs and Aditya Birla Sun Life AMC after strong technical breakouts, rising volumes and improving momentum indicators.

ABCAPITALABFRLABGSECABLBLABRELABSL10BANKABSLAMCABSLBANETFABSLLIQUIDABSLNN50ETABSLPSEAKUMSAONETMMQ50BIRLACORPNBIRLAMONEYBSLGOLDETFBSLNIFTYBSLSENETFGGLOBALGSEC10ABSLHEALTHYMOMENTUMNIFTYQLITYSILVERTECHConstruction MaterialsConsumer Services
Akums Drugs, subsidiary Akumentis Healthcare face ₹134 crore Income Tax demand
positive
CNBC TV18 - Markets 52d ago

Akums Drugs, subsidiary Akumentis Healthcare face ₹134 crore Income Tax demand

Shares of Akums Drugs and Pharmaceuticals Ltd ended at ₹513.00, down by ₹6.70, or 1.29%, on the BSE.

AAREYDRUGSAKUMSBSEHCGHCG-REHEALTHCAREMOHEALTHFinancial ServicesHealthcare
Akums Drugs Q4 profit declines, but EBITDA jumps 62%; declares special dividend
positive
CNBC TV18 - Markets 58d ago

Akums Drugs Q4 profit declines, but EBITDA jumps 62%; declares special dividend

Akums Drugs reported a mixed set of fourth-quarter earnings, with profit declining sharply despite healthy revenue growth and strong margin expansion, while the board announced a final and special dividend.

AKUMSDIVIDENDHEALTHYFinancial ServicesHealthcare